🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re announcing a new collaboration with Mammoth Biosciences that pairs their ultracompact CRISPR editing systems with our innovative delivery technologies, expanding our targeted gene editing abilities across multiple tissue and cell types. Learn more: bit.ly/49QYPKb

Join us in Baltimore for #ASGCT2024, where Mammoth will be presenting new preclinical data on our novel ultracompact CRISPR platform, as well as leading a symposium on advances in genome editing. We hope to see you there.

Watch Mammoth co-founder and CSO Lucas Harrington's oral presentation at #ASGCT2024, with new preclinical data on our platform's performance targeting the APOC3 gene, on Tuesday, May 7. Read the abstract: annualmeeting.asgct.org/abstracts/abst…

We're excited to be at #ASGCT2024 after the recent announcement of our collaboration with Regeneron. Mammoth co-founder & CSO Lucas Harrington will be sharing new preclinical data on our novel ultracompact CRISPR systems in an oral presentation today at 2:30 linkedin.com/feed/update/ur…

ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunities Mammoth Biosciences CSO Lucas Harrington lays out his company's big plans in developing a range of therapeutic options using miniature Cas nucleases...Read more: ow.ly/OlQf50RAbgL

Join us tomorrow morning at the BioNJ #BioPartnering Conference, where Mammoth's Chief Business Officer Phil Tinmouth will be taking part in the panel "BioPartnering: Keys to Success for Biotech and Pharma Partnerships."

This week on Inc. For Starters, I spoke with Trevor Martin (Trevor Martin), CEO + Co-Founder of Mammoth Biosciences, the platform revolutionizing CRISPR-based biology products across therapeutics + diagnostics. Their ultimate goal: finding permanent cures for genetic diseases.

Thanks Bayer AG and AskBio Inc. (AskBio) for hosting at the AskBio Philly office! We made lasting memories and are excited to continue our partnership to develop cutting-edge gene editing therapies to improve the lives of patients suffering from conditions difficult to treat. #CRISPR

Our Co-Founder Lucas Harrington discusses #invivo and #CRISPR with Erin Harris from Cell&Gene cellandgene.com/doc/tackling-t…

Thank you @WMIF2024, MassGeneral News Bank of America, for hosting our Co-Founder & CTO Lucas Harrington, on the "Deep Dive on Genetic Modalities for Rare Disease: Genetic Medicines Are Here" panel!

So excited to be a finalist in the Emerging Innovation category of the California Life Sciences (CLS) #PantheonAwards. We're working to cure diseases through in vivo gene editing with our ultra compact #CRISPR systems, so please support us with your vote! califesciences.org/pantheon-votin…

We are 1/2 through - have you voted? - Vote for Mammoth (Emerging Innovation): bit.ly/3U3qmTs - Like this and repost! Really proud of our ultracompact #CRISPR work to transform patients' lives and are grateful for the recognition that your vote and support brings! 😁

Last day to vote for Mammoth (Emerging Innovation): bit.ly/3U3qmTs!

We Won! Thank you everyone for your support, so proud of our work with #CRISPR, and thank you California Life Sciences (CLS)

📢Excited to introduce NanoCas -our new mini CRISPR system that can reach tissues previously out of reach! By shrinking CRISPR to 1/3 its normal size, we can now edit genes in muscle, heart & brain that were difficult to access before. Summary & link to paper:

We are proud to announce #NanoCas, our ultracompact #CRISPR system, overcomes gene editing limits, enabling efficient muscle editing in NHPs using a single AAV vector. 💡Curious to learn more? Read more here: businesswire.com/news/home/2025… #GeneEditing #Biotech #PrecisionMedicine

🧬CRISPR proteins shrink, but its potential expands! #NanoCas, featured in Science Magazine, edits NHP muscle via single-AAV delivery – unlocking therapies for hard-to-target diseases. Huge thanks to J Couzin-Frankel for covering our research! science.org/content/articl… #CRISPR #Biotech

🔬Our latest #NanoCas research is making waves! Thrilled to see Genetic Engineering & Biotechnology News coverage on #NanoCas!🎉 Our ultracompact nuclease enables single AAV delivery and efficient muscle editing in NHPs. A big thanks to Julianna LeMieux PhD and Genetic Engineering & Biotechnology News! genengnews.com/topics/genome-… #GeneEditing #Biotech

📢 In case you missed it, our latest study is now live! #NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues. 📄Read here: biorxiv.org/content/10.110… #CRISPR #GeneEditing #Biotech

We will be at #ASGCT25! Join us (in person or virtually) to hear about our latest results with NanoCas, the first efficient ultracompact extrahepatic gene editor. Despite its small size, NanoCas achieves efficient editing of muscle tissues in NHPs, a #CRISPR breakthrough.